ARMS2 variants may predict the 3-year outcome of photodynamic therapy for wet age-related macular degeneration

Similar Items

• A Common Complement C3 Variant Is Associated with Protection against Wet Age-Related Macular Degeneration in a Japanese Population
  od: Yanagisawa, Suiho, i dr.
  Izdano: (2011)
• Genetic factors associated with treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy
  od: Hayashida, Mayuka, i dr.
  Izdano: (2020)
• Difference between age-related macular degeneration and polypoidal choroidal vasculopathy in the hereditary contribution of the A69S variant of the age-related maculopathy susceptibility 2 gene (ARMS2)
  od: Yanagisawa, Suiho, i dr.
  Izdano: (2011)
• Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for macular edema secondary to central retinal vein occlusion
  od: Hirose, Miki, i dr.
  Izdano: (2014)
• Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity
  od: Hayashida, Mayuka, i dr.
  Izdano: (2020)